6th mRNA-Based Therapeutics Summit Returns to Boston with Focus on AI-Driven Design, In Vivo Cell Engineering, and Global Regulatory Harmonization
核心洞察
The 6th mRNA-Based Therapeutics Summit will convene 350+ global experts in Boston from July 20-22, 2026, featuring leaders from Moderna, Pfizer, AstraZeneca, Sanofi, and regulators including the FDA, MHRA, and EMA.
A new AI-Driven mRNA Design Day will showcase predictive modeling and sequence engineering solutions from Kernal Biologics, Sanofi, and Abogen Bio to accelerate mRNA development.
Dedicated sessions on in vivo cell engineering will highlight mRNA-LNP advances for cell therapy, with contributions from Parcel Bio, Inndura Therapeutics, and Nava Therapeutics.
The mRNA therapeutics field is entering a new era of scientific and commercial possibility, driven by rapid advances in in vivo CAR-T, gene editing, and cancer immunotherapy alongside headline-making acquisitions including Eli Lilly & Orna, BMS & Orbital, AbbVie & Capstan, and BioNTech & CureVac. Against this backdrop, the 6th mRNA-Based Therapeutics Summit returns to Boston this summer, bringing together over 350 global experts at the forefront of mRNA discovery, development, and delivery.
Scheduled for July 20-22, 2026, at The Westin Boston Seaport District, the summit features a refreshed three-track agenda with new focus days dedicated to AI-Driven mRNA Design and Next-Gen Delivery Technologies. The event positions itself as the premier meeting ground for those shaping the next generation of mRNA medicines.
Regulatory and Policy Insights Take Center Stage
A key highlight of the 2026 program is the regulatory and policy track, where experts from the European Medicines Agency (搜索) and Moderna will share perspectives on achieving global regulatory harmonization. The sessions aim to address the complex challenge of ensuring mRNA commercial success across different products and jurisdictions, a critical consideration as the modality expands beyond COVID-19 vaccines into broader therapeutic applications.
Industry Leaders and Emerging Innovators
The summit will feature direct insights from leading players rewriting mRNA's therapeutic potential, including Moderna, BioNTech, Pfizer, Sanofi, CREATE Medicines, Eli Lilly, Circurna, and Replicate Biosciences. Complementing these established voices, an Emerging Innovators Spotlight will showcase over 20 pioneering startups and world-leading biotechs, including CaVos Biotherapeutics, Cambridge Medixine, RNAvate, and Particella, presenting novel advances in linear mRNA, circular RNA, and saRNA design, delivery, and cutting-edge R&D strategies.
Inaugural AI & mRNA Design Day
Reflecting the growing intersection of artificial intelligence and nucleic acid therapeutics, the summit introduces its inaugural AI & mRNA Design Day. This dedicated track will explore predictive modeling and sequence engineering solutions accelerating mRNA development, with contributions from Kernal Biologics, Sanofi, and Abogen Bio. The integration of computational approaches into mRNA design represents a significant trend in the field, promising to streamline candidate optimization and reduce development timelines.
Advancing In Vivo Cell Engineering
With in vivo cell engineering increasingly capturing headlines, the summit offers fresh insight into mRNA-LNP capabilities to advance cell therapy. Sessions will feature Parcel Bio, Inndura Therapeutics, Nava Therapeutics, and other innovators working at the intersection of mRNA delivery and cellular reprogramming, highlighting the potential of lipid nanoparticle-based approaches to enable next-generation cell therapies without ex vivo manipulation.
The three-day program offers attendees unparalleled insights, partnership opportunities, and strategic guidance to accelerate mRNA pipelines worldwide, reflecting the field's rapid maturation from pandemic-era emergency response to a sustained, diversified therapeutic platform.